What OrigiMed does

OrigiMed (至本医疗科技有限公司) is a Shanghai-based precision oncology company founded in 2016 that operates a vertically integrated platform combining NGS-based tumor genetic testing, AI-powered diagnostic software, molecular tumor board (MTB) consultations, individualized ctDNA MRD monitoring, and a licensed internet hospital for direct patient access. Its core technology stack includes high-throughput NGS panels covering 700+ genes (DNA+RNA, liquid biopsy, and WES products under the Yuanhui/元溯, Yuanhui Liquid, Qingsuan/清源, and Zhixun/至寻 brands), nine proprietary bioinformatics algorithms including OriFusion, OriLongIndel, OriTMB, and OriMSI with published accuracy benchmarks, and a suite of AI products — SmartMTB (an LLM-based oncology diagnosis assistant), CUPU AI (EU CE-certified cancer-of-unknown-primary prediction), and OMSmartData (generative-AI data analytics). The company has 80+ invention patents, holds CAP, CLIA, ISO 27001, and NMPA Innovative Medical Device certifications, and has 100+ consecutive perfect proficiency scores across CAP, NCCL, and Shanghai Clinical Testing Center room-to-room assessments.

The business serves three customer layers: (i) 500+ tier-3 hospitals across China (covering 97% of core oncology hospitals) ordering clinical NGS tests, (ii) individual cancer patients accessing testing and consultations through the OrigiMed Precision Diagnosis Internet Hospital platform (10,000+ patients and 400+ doctors), and (iii) multinational pharmaceutical companies for companion diagnostic co-development, real-world studies, and patient recruitment — including Bayer (NTRK CDx), Takeda, Johnson & Johnson/Janssen, AstraZeneca, Menarini, and Roche. Revenue streams span per-test clinical service fees, multi-year pharma CDx and data projects with milestone and potential royalty components, subscription-style internet hospital services, and transaction fees from innovative insurance payment models with Ping An Health Insurance and other carriers. OrigiMed complements these services with an affiliated medical laboratory, a Jinan big data center, and a Quzhou IVD reagent production base under construction since November 2023. The company has been recognized among Forbes China high-growth gazelles (2020), Frost & Sullivan's digital oncology precision medicine leader (2022), and the China biotech innovation top 50 (2022), and presents research annually at ASCO, ESMO, AACR, and SIOP.

Name

OrigiMed

Legal name

至本医疗科技（上海）有限公司

Website

https://origimed.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Short description

OrigiMed (至本医疗) is a Shanghai-based precision oncology company founded in 2016 that delivers NGS-based tumor genetic testing, AI-assisted diagnosis, MRD monitoring, and licensed internet hospital services to cancer patients, 500+ Chinese tier-3 hospitals, and multinational pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Precision Oncology Diagnostics

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Companion Diagnostics (CDx) & Therapy Selection Assays (HLAAALAF), Companion Diagnostic (CDx) Co-Development Services (biopharma partnerships, clinical strategy) (HLAAAMAB), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Precision oncology diagnostics
• NGS genetic testing
• Companion diagnostics
• Minimal residual disease monitoring
• Molecular tumor board

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices6 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Genetic Testing Services: NGS-based tumor genetic testing services for individual patients ordered through hospitals and the internet hospital platform. Covers 700+ gene panels, DNA+RNA detection, MRD monitoring, and immunotherapy biomarker testing (TMB, MSI, PD-L1). Revenue generated per test, with follow-up surveillance and consultation services included.
2. Pharmaceutical Company Partnerships & CDx Development: One-stop custom solutions for anti-tumor drug R&D including clinical recruitment, real-world studies, data insights, and co-development of companion diagnostics. Revenue from project fees, milestone payments, and potential royalty streams from co-developed IVD products (e.g., Bayer NTRK CDx through NMPA innovative review).
3. Internet Hospital Services: Online molecular tumor board (MTB) consultations, NTRK specialty clinic, clinical trial matching and recruitment, and digital patient management platform services.
4. Innovation Insurance Payment: Collaborative insurance payment model with Ping An Health Insurance and other insurers, bundling genetic testing, molecular consultations, and drug access with insurance coverage, improving patient affordability and generating service fees.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

OrigiMed provides NGS-based cancer genetic testing services covering 700+ gene panels, ctDNA-based minimal residual disease (MRD) monitoring, AI-powered clinical decision support, and companion diagnostic (CDx) co-development for pharmaceutical companies. It operates a licensed internet hospital platform integrating molecular tumor board (MTB) consultations, recurrence monitoring, new drug matching, and innovative insurance payment solutions for cancer patients and oncologists across 500+ tier-3 hospitals in China.

Product overview

OrigiMed is a comprehensive precision oncology solution provider operating a platform-plus-products architecture. The core offering is the 至本精准诊疗互联网医院 (OrigiMed Precision Diagnosis & Treatment Internet Hospital), which integrates multiple modules including digital gene testing (数字化基因检测), MTB consultation (MTB会诊), recurrence monitoring/MRD (复发监测), new drug recommendation (新药推荐), and innovative payment solutions (创新支付). The product portfolio includes proprietary NGS diagnostic panels (元溯®系列, OriMIRACLE S™), AI-powered tools (SmartMTB, 至慧陪伴, CUPU AI, OMSmartData), and bioinformatics algorithms (OriFusion, OriLongindel, OriTMB, OriMSI). For pharmaceutical partners, OrigiMed offers companion diagnostics development, data innovation services, and central laboratory capabilities. The company also operates the 数知疗 data platform and provides specialized services like NTRK specialty clinic and international MTB consultations.

Differentiator

Problem solved

Functional benefit

Brands

• 至美OriMIRACLE: MRD dynamic monitoring product line for personalized tumor residual disease detection
• 元溯
• SmartMTB
• OMSmartData
• 康普(CUPU)
• 至本精准诊疗互联网医院
• 至慧陪伴
• 数知疗 (Datalore Cube)

Products and services

• OrigiMed Precision Diagnosis Internet Hospital (至本精准诊疗互联网医院) Licensed internet hospital platform providing online precision oncology diagnosis and treatment services for cancer patients and oncologists across China, integrating gene testing ordering, MTB consultation, recurrence monitoring, new drug recommendations, and innovative insurance payment.
• YuanSu S (元溯S) DNA+RNA Panel DNA+RNA combined NGS panel covering 700+ genes for comprehensive genomic profiling of solid tumors, including fusion detection. Used for solid tumor patients through hospital oncologists.
• YuanSu IO (元溯IO) Immunotherapy Panel DNA+IHC NGS panel covering 700+ genes designed for immunotherapy guidance in solid tumor patients, including TMB, MSI, and PD-L1 biomarkers.
• YuanSu Liquid (元溯Liquid) Liquid Biopsy Panel Liquid biopsy NGS panel covering 700+ genes for ctDNA analysis in solid tumor patients, enabling non-invasive genomic profiling.
• ClearSource (清源) Hematologic Malignancy Panel

Quantifiable outcome

• OriMSI algorithm achieves 99.5% accuracy, 98.8% sensitivity, and 99.7% specificity across multiple cancer types
• +4 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature9 records

Partnerships

15 partnerships are on record, tiered major, minor and core.

• Changhai Hospital (长海医院)majorStrategic or Co-development Partner · 1 January 2024OrigiMed and Changhai Hospital collaborated on renal cell carcinoma MRD detection research, with findings presented at ESMO 2024. The study validated the effectiveness of individualized MRD detection in renal cell carcinoma for predicting disease recurrence and metastasis risk.
• Fudan University Cancer Hospital (复旦大学附属肿瘤医院)majorStrategic or Co-development Partner · 1 January 2024Collaborative MRD research on metastatic colorectal cancer between OrigiMed and Fudan University Cancer Hospital was presented at ESMO 2024, bringing new hope and treatment strategies for colorectal cancer patients.
• Shanghai Pulmonary Hospital, Tongji University (同济大学上海市肺科医院)majorStrategic or Co-development Partner · 1 January 2024OrigiMed collaborated with Shanghai Pulmonary Hospital to develop a new clinical decision tool using machine learning on the Siyuan ICE AI platform, enabling prediction of immunotherapy response in NSCLC patients based on simple clinical features and biochemical indicators.
• HSBC Life (汇丰人寿)minorGTM or Marketing Partner · 8 November 2023OrigiMed Innovation Center GM Lu Tao was invited to attend the HSBC Life 'HSBC·Health' comprehensive health management program launch at CIIE 2023, exploring innovative insurance payment for precision oncology services.
• Bayer Healthcare (拜耳)coreGTM or Marketing Partner · 7 November 2023At CIIE 2023, Bayer Healthcare and OrigiMed signed a NTRK pan-cancer innovative cooperation agreement to further expand the partnership in precision oncology, building on their successful NTRK companion diagnostic development.
• CSCO Foundation / Ping An Health Insurance (CSCO基金会/平安健康保险)majorStrategic or Co-development Partner · 15 May 2023CSCO Foundation, Ping An Health Insurance, and OrigiMed announced a strategic cooperation in May 2023 to focus on the oncology precision diagnosis and treatment innovation ecosystem, combining clinical expertise, insurance resources, and precision medicine capabilities.
• CMAC (药物研发服务协会)minorStrategic or Co-development Partner · 8 April 2023OrigiMed co-hosted the 'CMAC Precision Diagnosis and Clinical Drug R&D Salon' in April 2023 with experts discussing how AI can assist oncology clinical research and how pharma and precision medicine companies can better collaborate. The CMAC Precision Diagnosis and Innovative Drug CLUB was officially established.
• Sun Yat-sen University First Affiliated Hospital (中山大学附属第一医院)majorStrategic or Co-development Partner · 1 January 2023Prof. Shen Jingnan and Prof. Yin Junqiang from the Bone Tumor Department collaborated with OrigiMed to launch China's first prospective, multi-center clinical study on sarcoma MRD in July 2023. The research on individualized MRD in sarcoma was selected for ASCO 2023 Clinical Science Seminar oral presentation.
• Ping An Health Insurance / Roche (平安健康保险/罗氏)coreGTM or Marketing Partner · 7 November 2022Ping An Health Insurance, Roche, and OrigiMed signed a strategic cooperation intention at CIIE 2022 to launch a pan-solid tumor rare靶点 innovative payment model for NTRK-positive patients, addressing actual medication affordability challenges.
• Hainan Boao Lecheng International Medical Tourism Pilot Zone Administration (博鳌乐城管理局)majorStrategic or Co-development Partner · 5 November 2022Lecheng Administration and OrigiMed signed a strategic cooperation MOU at CIIE 2022 to establish a comprehensive strategic partnership in medical innovation and clinical real-world data research, leveraging Lecheng's preferential policies.
• Menarini (美纳里尼)majorStrategic or Co-development Partner · 22 September 2022Italian biopharma Menarini and OrigiMed reached a strategic cooperation in September 2022 to deeply integrate各自 advantages and jointly build a pan-cancer single-cell molecular diagnosis innovation platform.
• Johnson & Johnson / Janssen China (强生/杨森)coreStrategic or Co-development Partner · 3 December 2021OrigiMed and Janssen (J&J) China R&D Center signed a Strategic Cooperation MOU in December 2021 to co-build clinical innovation solutions using real-world data and explore innovative use of RWD to accelerate clinical development.
• Takeda China (武田中国)coreStrategic or Co-development Partner · 1 January 2021Takeda China and OrigiMed signed strategic cooperation agreement at CIIE 2021 to build an innovative diagnosis-treatment integrated platform in the oncology field, leveraging each other's advantages to provide comprehensive solutions for cancer patients.
• AstraZenecacoreStrategic or Co-development Partner · 1 January 2021OrigiMed signed a strategic cooperation with AstraZeneca in 2021 to establish a precision diagnosis integrated innovation alliance, using the internet medical platform to provide individualized precision diagnosis full-process solutions for patients.
• Bayer Healthcare (拜耳)coreStrategic or Co-development Partner · 1 January 2020Bayer and OrigiMed announced innovative pan-cancer companion diagnostic development cooperation in early 2020. The Human NTRK1/2/3 Genomic Alteration Testing Kit (reversible terminator sequencing method) was granted NMPA Special Review Procedure for Innovative Medical Devices in August 2021. Cooperation expanded at CIIE 2021 and 2023 for NTRK pan-cancer innovative partnership.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Burning Rock Biotech: Leading China-based NGS oncology diagnostics company with comparable 500+ gene panels, hospital sales model, pharma CDx partnerships, and CAP/CLIA-certified labs. Directly competes with OrigiMed in Chinese tier-3 hospital channel for solid tumor NGS testing.
• Geneseeq Technology: Major Chinese NGS oncology company offering similar comprehensive gene panel testing, MRD monitoring, and pharma CDx development services. Directly competes with OrigiMed across clinical NGS testing and pharma collaborations in China.
• Amoy Diagnostics: China-based molecular diagnostics company specializing in PCR and NGS-based oncology companion diagnostics, including multiple NMPA-approved CDx kits. Direct competitor in CDx development and oncology testing with strong pharma partnerships.
• Berry Oncology: Chinese precision oncology company offering NGS-based tumor profiling, MRD monitoring, and early cancer detection services. Directly competes with OrigiMed in Chinese hospital NGS testing and pharma services markets.
• 3D Medicines: China-based precision oncology company with NGS-based diagnostics, MRD products, and pharma R&D services including companion diagnostics co-development. Competes directly with OrigiMed in Chinese hospital NGS testing market.

Broad incumbents

• Guardant Health: US-based liquid biopsy and precision oncology leader offering Guardant360 ctDNA panel and Guardant Reveal MRD product. Operates in same NGS oncology diagnostics space but at larger US-focused scale and serves as a broader portfolio player in precision oncology.
• Foundation Medicine: Roche subsidiary offering comprehensive genomic profiling (FoundationOne CDx) widely used for oncology CDx globally. Operates as a broad incumbent in NGS-based oncology diagnostics with overlapping pharma CDx development capabilities.
• Caris Life Sciences: US-based molecular profiling and AI company offering Caris Molecular Intelligence whole-exome and whole-transcriptome sequencing for oncology. Broad incumbent with overlapping NGS oncology testing and AI-driven diagnostic capabilities, but primarily serves US market.
• Tempus AI: US-based precision medicine company combining NGS molecular profiling with proprietary data library and AI for oncology. Broad incumbent with overlapping NGS testing, AI diagnostics, and pharma RWD offerings, but at larger scale and US-focused.

Emerging players

• Personalis: US-based NGS company specializing in ImmunoID Next tumor profiling and NeXT Personal MRD monitoring. Emerging peer with overlapping NGS oncology and MRD product focus but smaller scale and US market concentration.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OrigiMed